tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Summit Therapeutics’ Ivonescimab: A Promising Competitor to Keytruda with Increased Approval Probability and Price Target
PremiumRatingsSummit Therapeutics’ Ivonescimab: A Promising Competitor to Keytruda with Increased Approval Probability and Price Target
6d ago
Summit Therapeutics put volume heavy and directionally bearish
Premium
The Fly
Summit Therapeutics put volume heavy and directionally bearish
11d ago
Summit Therapeutics put volume heavy and directionally bearish
Premium
The Fly
Summit Therapeutics put volume heavy and directionally bearish
14d ago
Summit going concern language ‘non-issue,’ says Citi
PremiumThe FlySummit going concern language ‘non-issue,’ says Citi
21d ago
Summit Therapeutics notes ‘doubt’ about ability to continue as ‘going concern’
Premium
The Fly
Summit Therapeutics notes ‘doubt’ about ability to continue as ‘going concern’
21d ago
Summit Therapeutics falls -12.5%
Premium
The Fly
Summit Therapeutics falls -12.5%
21d ago
Summit Therapeutics Amends Stock Distribution Agreement
PremiumCompany AnnouncementsSummit Therapeutics Amends Stock Distribution Agreement
22d ago
Summit Therapeutics reports Q2 non-GAAP EPS (12c) , consensus (7c)
Premium
The Fly
Summit Therapeutics reports Q2 non-GAAP EPS (12c) , consensus (7c)
22d ago
Summit Therapeutics Advances in Metastatic Colorectal Cancer Treatment with Phase II Trial
Premium
Company Announcements
Summit Therapeutics Advances in Metastatic Colorectal Cancer Treatment with Phase II Trial
25d ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100